Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
47.82
-1.69 (-3.41%)
At close: Nov 14, 2024, 4:00 PM
48.15
+0.33 (0.69%)
Pre-market: Nov 15, 2024, 8:13 AM EST
Sanofi Employees
Sanofi had 86,088 employees as of December 31, 2023. The number of employees decreased by 5,485 or -5.99% compared to the previous year.
Employees
86,088
Change (1Y)
-5,485
Growth (1Y)
-5.99%
Revenue / Employee
$627,636
Profits / Employee
$58,378
Market Cap
125.20B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
Dec 31, 2020 | 99,412 | -997 | -0.99% |
Dec 31, 2019 | 100,409 | -3,817 | -3.66% |
Dec 31, 2018 | 104,226 | -2,340 | -2.20% |
Dec 31, 2017 | 106,566 | -293 | -0.27% |
Dec 31, 2016 | 106,859 | -2,230 | -2.04% |
Dec 31, 2015 | 109,089 | 1,702 | 1.58% |
Dec 31, 2014 | 107,387 | -4,741 | -4.23% |
Dec 31, 2013 | 112,128 | 154 | 0.14% |
Dec 31, 2012 | 111,974 | -1,745 | -1.53% |
Dec 31, 2011 | 113,719 | 12,144 | 11.96% |
Dec 31, 2010 | 101,575 | -3,292 | -3.14% |
Dec 31, 2009 | 104,867 | 6,654 | 6.78% |
Dec 31, 2008 | 98,213 | -1,282 | -1.29% |
Dec 31, 2007 | 99,495 | -794 | -0.79% |
Dec 31, 2006 | 100,289 | 3,108 | 3.20% |
Dec 31, 2005 | 97,181 | 742 | 0.77% |
Dec 31, 2004 | 96,439 | 63,353 | 191.48% |
Dec 31, 2003 | 33,086 | 650 | 2.00% |
Dec 31, 2002 | 32,436 | 1,922 | 6.30% |
Dec 31, 2001 | 30,514 | 1,314 | 4.50% |
Dec 31, 2000 | 29,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Elevance Health | 104,900 |
Medtronic | 95,000 |
Pfizer | 88,000 |
The Cigna Group | 72,500 |
Boston Scientific | 48,000 |
Bristol-Myers Squibb Company | 34,100 |
Amgen | 26,700 |
Stryker | 26,700 |
SNY News
- 20 hours ago - Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma - GlobeNewsWire
- 2 days ago - Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform - Business Wire
- 2 days ago - Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive - Seeking Alpha
- 7 days ago - The Accumulus Platform Powers Sanofi's Submissions to Multiple Regulators Around the World - GlobeNewsWire
- 9 days ago - Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis - GlobeNewsWire
- 15 days ago - Sanofi Cancels Consumer Healthcare Business Spin-Off - Forbes
- 18 days ago - Resalis Therapeutics Gains Strategic Equity Investment from Sanofi - Business Wire
- 20 days ago - Sanofi (SNY) Q3 2024 Earnings Call Transcript - Seeking Alpha